nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A7—Simvastatin—atherosclerosis	0.0726	0.0943	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0726	0.0943	CbGbCtD
Salmeterol—CYP3A7—Lovastatin—atherosclerosis	0.0711	0.0923	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0711	0.0923	CbGbCtD
Salmeterol—CYP3A5—Rosuvastatin—atherosclerosis	0.0586	0.0761	CbGbCtD
Salmeterol—CYP3A5—Simvastatin—atherosclerosis	0.0545	0.0707	CbGbCtD
Salmeterol—CYP3A5—Pravastatin—atherosclerosis	0.0533	0.0692	CbGbCtD
Salmeterol—CYP3A5—Lovastatin—atherosclerosis	0.0533	0.0692	CbGbCtD
Salmeterol—CYP2C8—Simvastatin—atherosclerosis	0.0524	0.068	CbGbCtD
Salmeterol—CYP2C8—Pravastatin—atherosclerosis	0.0513	0.0665	CbGbCtD
Salmeterol—CYP2C8—Lovastatin—atherosclerosis	0.0513	0.0665	CbGbCtD
Salmeterol—CYP3A4—Rosuvastatin—atherosclerosis	0.0229	0.0297	CbGbCtD
Salmeterol—CYP3A4—Ezetimibe—atherosclerosis	0.0229	0.0297	CbGbCtD
Salmeterol—CYP3A4—Simvastatin—atherosclerosis	0.0212	0.0276	CbGbCtD
Salmeterol—CYP3A4—Lovastatin—atherosclerosis	0.0208	0.027	CbGbCtD
Salmeterol—CYP3A4—Pravastatin—atherosclerosis	0.0208	0.027	CbGbCtD
Salmeterol—Nasopharyngitis—Ezetimibe—atherosclerosis	0.000851	0.00415	CcSEcCtD
Salmeterol—Influenza—Lovastatin—atherosclerosis	0.000839	0.00409	CcSEcCtD
Salmeterol—Sinusitis—Rosuvastatin—atherosclerosis	0.000828	0.00404	CcSEcCtD
Salmeterol—Influenza—Ezetimibe—atherosclerosis	0.000823	0.00401	CcSEcCtD
Salmeterol—Migraine—Niacin—atherosclerosis	0.000821	0.004	CcSEcCtD
Salmeterol—Cramp muscle—Simvastatin—atherosclerosis	0.000818	0.00399	CcSEcCtD
Salmeterol—Abdominal discomfort—Lovastatin—atherosclerosis	0.000804	0.00392	CcSEcCtD
Salmeterol—Rhinitis—Rosuvastatin—atherosclerosis	0.000794	0.00387	CcSEcCtD
Salmeterol—Pharyngitis—Rosuvastatin—atherosclerosis	0.000786	0.00383	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Ezetimibe—atherosclerosis	0.000765	0.00373	CcSEcCtD
Salmeterol—Bronchitis—Simvastatin—atherosclerosis	0.000755	0.00368	CcSEcCtD
Salmeterol—Abdominal discomfort—Simvastatin—atherosclerosis	0.000752	0.00367	CcSEcCtD
Salmeterol—Cramp muscle—Pravastatin—atherosclerosis	0.000739	0.0036	CcSEcCtD
Salmeterol—Nasopharyngitis—Pravastatin—atherosclerosis	0.000734	0.00358	CcSEcCtD
Salmeterol—Infestation—Ezetimibe—atherosclerosis	0.000734	0.00358	CcSEcCtD
Salmeterol—Infestation NOS—Ezetimibe—atherosclerosis	0.000734	0.00358	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000729	0.00356	CcSEcCtD
Salmeterol—Urinary tract infection—Lovastatin—atherosclerosis	0.000727	0.00354	CcSEcCtD
Salmeterol—Influenza—Niacin—atherosclerosis	0.000721	0.00351	CcSEcCtD
Salmeterol—Influenza—Pravastatin—atherosclerosis	0.000709	0.00346	CcSEcCtD
Salmeterol—Arrhythmia—Rosuvastatin—atherosclerosis	0.000708	0.00345	CcSEcCtD
Salmeterol—Sinusitis—Lovastatin—atherosclerosis	0.000702	0.00342	CcSEcCtD
Salmeterol—Mental disorder—Rosuvastatin—atherosclerosis	0.000694	0.00338	CcSEcCtD
Salmeterol—Bronchitis—Niacin—atherosclerosis	0.000693	0.00338	CcSEcCtD
Salmeterol—Sinusitis—Ezetimibe—atherosclerosis	0.000688	0.00336	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000659	0.00321	CcSEcCtD
Salmeterol—Sinusitis—Simvastatin—atherosclerosis	0.000656	0.0032	CcSEcCtD
Salmeterol—Pharyngitis—Ezetimibe—atherosclerosis	0.000654	0.00319	CcSEcCtD
Salmeterol—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000647	0.00316	CcSEcCtD
Salmeterol—Angioedema—Rosuvastatin—atherosclerosis	0.00063	0.00307	CcSEcCtD
Salmeterol—Urinary tract infection—Pravastatin—atherosclerosis	0.000615	0.003	CcSEcCtD
Salmeterol—Cough—Rosuvastatin—atherosclerosis	0.000602	0.00293	CcSEcCtD
Salmeterol—Immune system disorder—Ezetimibe—atherosclerosis	0.000595	0.0029	CcSEcCtD
Salmeterol—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000594	0.00289	CcSEcCtD
Salmeterol—Sinusitis—Pravastatin—atherosclerosis	0.000593	0.00289	CcSEcCtD
Salmeterol—Arthralgia—Rosuvastatin—atherosclerosis	0.000587	0.00286	CcSEcCtD
Salmeterol—Myalgia—Rosuvastatin—atherosclerosis	0.000587	0.00286	CcSEcCtD
Salmeterol—Rhinitis—Niacin—atherosclerosis	0.000578	0.00282	CcSEcCtD
Salmeterol—Mental disorder—Ezetimibe—atherosclerosis	0.000577	0.00281	CcSEcCtD
Salmeterol—Malnutrition—Ezetimibe—atherosclerosis	0.000573	0.0028	CcSEcCtD
Salmeterol—Rhinitis—Pravastatin—atherosclerosis	0.000569	0.00278	CcSEcCtD
Salmeterol—Back pain—Lovastatin—atherosclerosis	0.000565	0.00276	CcSEcCtD
Salmeterol—Pharyngitis—Pravastatin—atherosclerosis	0.000564	0.00275	CcSEcCtD
Salmeterol—Muscle spasms—Lovastatin—atherosclerosis	0.000562	0.00274	CcSEcCtD
Salmeterol—Infection—Rosuvastatin—atherosclerosis	0.000559	0.00273	CcSEcCtD
Salmeterol—Back pain—Ezetimibe—atherosclerosis	0.000555	0.0027	CcSEcCtD
Salmeterol—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000552	0.00269	CcSEcCtD
Salmeterol—Muscle spasms—Ezetimibe—atherosclerosis	0.000551	0.00269	CcSEcCtD
Salmeterol—Mental disorder—Simvastatin—atherosclerosis	0.00055	0.00268	CcSEcCtD
Salmeterol—Tremor—Lovastatin—atherosclerosis	0.000548	0.00267	CcSEcCtD
Salmeterol—Ill-defined disorder—Lovastatin—atherosclerosis	0.000542	0.00264	CcSEcCtD
Salmeterol—Angioedema—Lovastatin—atherosclerosis	0.000534	0.0026	CcSEcCtD
Salmeterol—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000532	0.00259	CcSEcCtD
Salmeterol—Malaise—Lovastatin—atherosclerosis	0.000527	0.00257	CcSEcCtD
Salmeterol—Cardiac disorder—Pravastatin—atherosclerosis	0.000527	0.00257	CcSEcCtD
Salmeterol—Muscle spasms—Simvastatin—atherosclerosis	0.000526	0.00256	CcSEcCtD
Salmeterol—Angioedema—Ezetimibe—atherosclerosis	0.000524	0.00255	CcSEcCtD
Salmeterol—Malaise—Ezetimibe—atherosclerosis	0.000517	0.00252	CcSEcCtD
Salmeterol—Arrhythmia—Niacin—atherosclerosis	0.000515	0.00251	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000513	0.0025	CcSEcCtD
Salmeterol—Tremor—Simvastatin—atherosclerosis	0.000512	0.0025	CcSEcCtD
Salmeterol—Insomnia—Rosuvastatin—atherosclerosis	0.000509	0.00248	CcSEcCtD
Salmeterol—Ill-defined disorder—Simvastatin—atherosclerosis	0.000507	0.00247	CcSEcCtD
Salmeterol—Arrhythmia—Pravastatin—atherosclerosis	0.000507	0.00247	CcSEcCtD
Salmeterol—Palpitations—Ezetimibe—atherosclerosis	0.000507	0.00247	CcSEcCtD
Salmeterol—Paraesthesia—Rosuvastatin—atherosclerosis	0.000506	0.00246	CcSEcCtD
Salmeterol—Malnutrition—Niacin—atherosclerosis	0.000502	0.00245	CcSEcCtD
Salmeterol—Cough—Ezetimibe—atherosclerosis	0.0005	0.00244	CcSEcCtD
Salmeterol—Angioedema—Simvastatin—atherosclerosis	0.0005	0.00244	CcSEcCtD
Salmeterol—Arthralgia—Lovastatin—atherosclerosis	0.000498	0.00243	CcSEcCtD
Salmeterol—Myalgia—Lovastatin—atherosclerosis	0.000498	0.00243	CcSEcCtD
Salmeterol—Chest pain—Lovastatin—atherosclerosis	0.000498	0.00243	CcSEcCtD
Salmeterol—Anxiety—Lovastatin—atherosclerosis	0.000496	0.00242	CcSEcCtD
Salmeterol—Dyspepsia—Rosuvastatin—atherosclerosis	0.000496	0.00242	CcSEcCtD
Salmeterol—Hypertension—Ezetimibe—atherosclerosis	0.000495	0.00241	CcSEcCtD
Salmeterol—Malaise—Simvastatin—atherosclerosis	0.000493	0.0024	CcSEcCtD
Salmeterol—Tension—Niacin—atherosclerosis	0.000493	0.0024	CcSEcCtD
Salmeterol—Discomfort—Lovastatin—atherosclerosis	0.000492	0.0024	CcSEcCtD
Salmeterol—Myalgia—Ezetimibe—atherosclerosis	0.000488	0.00238	CcSEcCtD
Salmeterol—Chest pain—Ezetimibe—atherosclerosis	0.000488	0.00238	CcSEcCtD
Salmeterol—Arthralgia—Ezetimibe—atherosclerosis	0.000488	0.00238	CcSEcCtD
Salmeterol—Nervousness—Niacin—atherosclerosis	0.000488	0.00238	CcSEcCtD
Salmeterol—Dry mouth—Lovastatin—atherosclerosis	0.000487	0.00237	CcSEcCtD
Salmeterol—Tension—Pravastatin—atherosclerosis	0.000485	0.00237	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000485	0.00236	CcSEcCtD
Salmeterol—Muscle spasms—Niacin—atherosclerosis	0.000483	0.00235	CcSEcCtD
Salmeterol—Discomfort—Ezetimibe—atherosclerosis	0.000482	0.00235	CcSEcCtD
Salmeterol—Constipation—Rosuvastatin—atherosclerosis	0.000481	0.00235	CcSEcCtD
Salmeterol—Pain—Rosuvastatin—atherosclerosis	0.000481	0.00235	CcSEcCtD
Salmeterol—Nervousness—Pravastatin—atherosclerosis	0.00048	0.00234	CcSEcCtD
Salmeterol—Dry mouth—Ezetimibe—atherosclerosis	0.000477	0.00233	CcSEcCtD
Salmeterol—Anaphylactic shock—Lovastatin—atherosclerosis	0.000477	0.00233	CcSEcCtD
Salmeterol—Muscle spasms—Pravastatin—atherosclerosis	0.000475	0.00232	CcSEcCtD
Salmeterol—Infection—Lovastatin—atherosclerosis	0.000474	0.00231	CcSEcCtD
Salmeterol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000468	0.00228	CcSEcCtD
Salmeterol—Arthralgia—Simvastatin—atherosclerosis	0.000466	0.00227	CcSEcCtD
Salmeterol—Chest pain—Simvastatin—atherosclerosis	0.000466	0.00227	CcSEcCtD
Salmeterol—Myalgia—Simvastatin—atherosclerosis	0.000466	0.00227	CcSEcCtD
Salmeterol—Infection—Ezetimibe—atherosclerosis	0.000465	0.00227	CcSEcCtD
Salmeterol—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000464	0.00226	CcSEcCtD
Salmeterol—Anxiety—Simvastatin—atherosclerosis	0.000464	0.00226	CcSEcCtD
Salmeterol—Tremor—Pravastatin—atherosclerosis	0.000463	0.00226	CcSEcCtD
Salmeterol—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00046	0.00224	CcSEcCtD
Salmeterol—Discomfort—Simvastatin—atherosclerosis	0.00046	0.00224	CcSEcCtD
Salmeterol—Nervous system disorder—Ezetimibe—atherosclerosis	0.000459	0.00224	CcSEcCtD
Salmeterol—Angioedema—Niacin—atherosclerosis	0.000459	0.00224	CcSEcCtD
Salmeterol—Ill-defined disorder—Pravastatin—atherosclerosis	0.000459	0.00224	CcSEcCtD
Salmeterol—Skin disorder—Ezetimibe—atherosclerosis	0.000455	0.00222	CcSEcCtD
Salmeterol—Angioedema—Pravastatin—atherosclerosis	0.000452	0.0022	CcSEcCtD
Salmeterol—Urticaria—Rosuvastatin—atherosclerosis	0.000447	0.00218	CcSEcCtD
Salmeterol—Oedema—Simvastatin—atherosclerosis	0.000446	0.00218	CcSEcCtD
Salmeterol—Anaphylactic shock—Simvastatin—atherosclerosis	0.000446	0.00218	CcSEcCtD
Salmeterol—Malaise—Pravastatin—atherosclerosis	0.000446	0.00217	CcSEcCtD
Salmeterol—Abdominal pain—Rosuvastatin—atherosclerosis	0.000445	0.00217	CcSEcCtD
Salmeterol—Palpitations—Niacin—atherosclerosis	0.000444	0.00216	CcSEcCtD
Salmeterol—Infection—Simvastatin—atherosclerosis	0.000443	0.00216	CcSEcCtD
Salmeterol—Cough—Niacin—atherosclerosis	0.000438	0.00214	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000435	0.00212	CcSEcCtD
Salmeterol—Insomnia—Lovastatin—atherosclerosis	0.000432	0.0021	CcSEcCtD
Salmeterol—Cough—Pravastatin—atherosclerosis	0.000431	0.0021	CcSEcCtD
Salmeterol—Paraesthesia—Lovastatin—atherosclerosis	0.000428	0.00209	CcSEcCtD
Salmeterol—Arthralgia—Niacin—atherosclerosis	0.000427	0.00208	CcSEcCtD
Salmeterol—Myalgia—Niacin—atherosclerosis	0.000427	0.00208	CcSEcCtD
Salmeterol—Hypertension—Pravastatin—atherosclerosis	0.000427	0.00208	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000426	0.00208	CcSEcCtD
Salmeterol—Dyspnoea—Lovastatin—atherosclerosis	0.000425	0.00207	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000425	0.00207	CcSEcCtD
Salmeterol—Insomnia—Ezetimibe—atherosclerosis	0.000423	0.00206	CcSEcCtD
Salmeterol—Arthralgia—Pravastatin—atherosclerosis	0.000421	0.00205	CcSEcCtD
Salmeterol—Chest pain—Pravastatin—atherosclerosis	0.000421	0.00205	CcSEcCtD
Salmeterol—Myalgia—Pravastatin—atherosclerosis	0.000421	0.00205	CcSEcCtD
Salmeterol—Paraesthesia—Ezetimibe—atherosclerosis	0.00042	0.00205	CcSEcCtD
Salmeterol—Dyspepsia—Lovastatin—atherosclerosis	0.00042	0.00205	CcSEcCtD
Salmeterol—Anxiety—Pravastatin—atherosclerosis	0.000419	0.00204	CcSEcCtD
Salmeterol—Dry mouth—Niacin—atherosclerosis	0.000418	0.00204	CcSEcCtD
Salmeterol—Dyspnoea—Ezetimibe—atherosclerosis	0.000417	0.00203	CcSEcCtD
Salmeterol—Discomfort—Pravastatin—atherosclerosis	0.000416	0.00203	CcSEcCtD
Salmeterol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000415	0.00202	CcSEcCtD
Salmeterol—Dyspepsia—Ezetimibe—atherosclerosis	0.000412	0.00201	CcSEcCtD
Salmeterol—Fatigue—Lovastatin—atherosclerosis	0.000411	0.00201	CcSEcCtD
Salmeterol—Oedema—Niacin—atherosclerosis	0.00041	0.002	CcSEcCtD
Salmeterol—Anaphylactic shock—Niacin—atherosclerosis	0.00041	0.002	CcSEcCtD
Salmeterol—Constipation—Lovastatin—atherosclerosis	0.000408	0.00199	CcSEcCtD
Salmeterol—Pain—Lovastatin—atherosclerosis	0.000408	0.00199	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000407	0.00198	CcSEcCtD
Salmeterol—Asthenia—Rosuvastatin—atherosclerosis	0.000404	0.00197	CcSEcCtD
Salmeterol—Insomnia—Simvastatin—atherosclerosis	0.000404	0.00197	CcSEcCtD
Salmeterol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000403	0.00197	CcSEcCtD
Salmeterol—Oedema—Pravastatin—atherosclerosis	0.000403	0.00197	CcSEcCtD
Salmeterol—Fatigue—Ezetimibe—atherosclerosis	0.000403	0.00197	CcSEcCtD
Salmeterol—Infection—Pravastatin—atherosclerosis	0.000401	0.00195	CcSEcCtD
Salmeterol—Paraesthesia—Simvastatin—atherosclerosis	0.000401	0.00195	CcSEcCtD
Salmeterol—Pain—Ezetimibe—atherosclerosis	0.0004	0.00195	CcSEcCtD
Salmeterol—Constipation—Ezetimibe—atherosclerosis	0.0004	0.00195	CcSEcCtD
Salmeterol—Tachycardia—Niacin—atherosclerosis	0.0004	0.00195	CcSEcCtD
Salmeterol—Skin disorder—Niacin—atherosclerosis	0.000398	0.00194	CcSEcCtD
Salmeterol—Dyspnoea—Simvastatin—atherosclerosis	0.000398	0.00194	CcSEcCtD
Salmeterol—Feeling abnormal—Lovastatin—atherosclerosis	0.000393	0.00192	CcSEcCtD
Salmeterol—Dyspepsia—Simvastatin—atherosclerosis	0.000393	0.00192	CcSEcCtD
Salmeterol—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00039	0.0019	CcSEcCtD
Salmeterol—Feeling abnormal—Ezetimibe—atherosclerosis	0.000386	0.00188	CcSEcCtD
Salmeterol—Diarrhoea—Rosuvastatin—atherosclerosis	0.000385	0.00188	CcSEcCtD
Salmeterol—Fatigue—Simvastatin—atherosclerosis	0.000385	0.00188	CcSEcCtD
Salmeterol—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000383	0.00187	CcSEcCtD
Salmeterol—Constipation—Simvastatin—atherosclerosis	0.000382	0.00186	CcSEcCtD
Salmeterol—Pain—Simvastatin—atherosclerosis	0.000382	0.00186	CcSEcCtD
Salmeterol—Urticaria—Lovastatin—atherosclerosis	0.000379	0.00185	CcSEcCtD
Salmeterol—Abdominal pain—Lovastatin—atherosclerosis	0.000377	0.00184	CcSEcCtD
Salmeterol—Body temperature increased—Lovastatin—atherosclerosis	0.000377	0.00184	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000373	0.00182	CcSEcCtD
Salmeterol—Dizziness—Rosuvastatin—atherosclerosis	0.000372	0.00181	CcSEcCtD
Salmeterol—Urticaria—Ezetimibe—atherosclerosis	0.000372	0.00181	CcSEcCtD
Salmeterol—Insomnia—Niacin—atherosclerosis	0.000371	0.00181	CcSEcCtD
Salmeterol—Body temperature increased—Ezetimibe—atherosclerosis	0.00037	0.0018	CcSEcCtD
Salmeterol—Abdominal pain—Ezetimibe—atherosclerosis	0.00037	0.0018	CcSEcCtD
Salmeterol—Paraesthesia—Niacin—atherosclerosis	0.000368	0.00179	CcSEcCtD
Salmeterol—Feeling abnormal—Simvastatin—atherosclerosis	0.000368	0.00179	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000368	0.00179	CcSEcCtD
Salmeterol—Dyspnoea—Niacin—atherosclerosis	0.000365	0.00178	CcSEcCtD
Salmeterol—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000365	0.00178	CcSEcCtD
Salmeterol—Insomnia—Pravastatin—atherosclerosis	0.000365	0.00178	CcSEcCtD
Salmeterol—Paraesthesia—Pravastatin—atherosclerosis	0.000362	0.00177	CcSEcCtD
Salmeterol—Dyspepsia—Niacin—atherosclerosis	0.000361	0.00176	CcSEcCtD
Salmeterol—Dyspnoea—Pravastatin—atherosclerosis	0.00036	0.00175	CcSEcCtD
Salmeterol—Dyspepsia—Pravastatin—atherosclerosis	0.000355	0.00173	CcSEcCtD
Salmeterol—Rash—Rosuvastatin—atherosclerosis	0.000355	0.00173	CcSEcCtD
Salmeterol—Dermatitis—Rosuvastatin—atherosclerosis	0.000355	0.00173	CcSEcCtD
Salmeterol—Urticaria—Simvastatin—atherosclerosis	0.000355	0.00173	CcSEcCtD
Salmeterol—Body temperature increased—Simvastatin—atherosclerosis	0.000353	0.00172	CcSEcCtD
Salmeterol—Abdominal pain—Simvastatin—atherosclerosis	0.000353	0.00172	CcSEcCtD
Salmeterol—Headache—Rosuvastatin—atherosclerosis	0.000353	0.00172	CcSEcCtD
Salmeterol—Hypersensitivity—Lovastatin—atherosclerosis	0.000352	0.00171	CcSEcCtD
Salmeterol—Pain—Niacin—atherosclerosis	0.00035	0.00171	CcSEcCtD
Salmeterol—Fatigue—Pravastatin—atherosclerosis	0.000348	0.0017	CcSEcCtD
Salmeterol—Pain—Pravastatin—atherosclerosis	0.000345	0.00168	CcSEcCtD
Salmeterol—Constipation—Pravastatin—atherosclerosis	0.000345	0.00168	CcSEcCtD
Salmeterol—Hypersensitivity—Ezetimibe—atherosclerosis	0.000345	0.00168	CcSEcCtD
Salmeterol—Asthenia—Lovastatin—atherosclerosis	0.000342	0.00167	CcSEcCtD
Salmeterol—Asthenia—Ezetimibe—atherosclerosis	0.000336	0.00164	CcSEcCtD
Salmeterol—Gastrointestinal pain—Niacin—atherosclerosis	0.000335	0.00163	CcSEcCtD
Salmeterol—Nausea—Rosuvastatin—atherosclerosis	0.000334	0.00163	CcSEcCtD
Salmeterol—Feeling abnormal—Pravastatin—atherosclerosis	0.000332	0.00162	CcSEcCtD
Salmeterol—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00033	0.00161	CcSEcCtD
Salmeterol—Hypersensitivity—Simvastatin—atherosclerosis	0.000329	0.0016	CcSEcCtD
Salmeterol—Diarrhoea—Lovastatin—atherosclerosis	0.000326	0.00159	CcSEcCtD
Salmeterol—Urticaria—Niacin—atherosclerosis	0.000326	0.00159	CcSEcCtD
Salmeterol—Body temperature increased—Niacin—atherosclerosis	0.000324	0.00158	CcSEcCtD
Salmeterol—Abdominal pain—Niacin—atherosclerosis	0.000324	0.00158	CcSEcCtD
Salmeterol—Urticaria—Pravastatin—atherosclerosis	0.000321	0.00156	CcSEcCtD
Salmeterol—Asthenia—Simvastatin—atherosclerosis	0.00032	0.00156	CcSEcCtD
Salmeterol—Diarrhoea—Ezetimibe—atherosclerosis	0.00032	0.00156	CcSEcCtD
Salmeterol—Body temperature increased—Pravastatin—atherosclerosis	0.000319	0.00155	CcSEcCtD
Salmeterol—Abdominal pain—Pravastatin—atherosclerosis	0.000319	0.00155	CcSEcCtD
Salmeterol—Dizziness—Lovastatin—atherosclerosis	0.000315	0.00154	CcSEcCtD
Salmeterol—Dizziness—Ezetimibe—atherosclerosis	0.000309	0.00151	CcSEcCtD
Salmeterol—Diarrhoea—Simvastatin—atherosclerosis	0.000305	0.00149	CcSEcCtD
Salmeterol—Vomiting—Lovastatin—atherosclerosis	0.000303	0.00148	CcSEcCtD
Salmeterol—Hypersensitivity—Niacin—atherosclerosis	0.000302	0.00147	CcSEcCtD
Salmeterol—Rash—Lovastatin—atherosclerosis	0.000301	0.00147	CcSEcCtD
Salmeterol—Dermatitis—Lovastatin—atherosclerosis	0.000301	0.00147	CcSEcCtD
Salmeterol—Headache—Lovastatin—atherosclerosis	0.000299	0.00146	CcSEcCtD
Salmeterol—Vomiting—Ezetimibe—atherosclerosis	0.000298	0.00145	CcSEcCtD
Salmeterol—Hypersensitivity—Pravastatin—atherosclerosis	0.000297	0.00145	CcSEcCtD
Salmeterol—Dizziness—Simvastatin—atherosclerosis	0.000295	0.00144	CcSEcCtD
Salmeterol—Rash—Ezetimibe—atherosclerosis	0.000295	0.00144	CcSEcCtD
Salmeterol—Dermatitis—Ezetimibe—atherosclerosis	0.000295	0.00144	CcSEcCtD
Salmeterol—Asthenia—Niacin—atherosclerosis	0.000294	0.00143	CcSEcCtD
Salmeterol—Headache—Ezetimibe—atherosclerosis	0.000293	0.00143	CcSEcCtD
Salmeterol—Asthenia—Pravastatin—atherosclerosis	0.000289	0.00141	CcSEcCtD
Salmeterol—Vomiting—Simvastatin—atherosclerosis	0.000284	0.00138	CcSEcCtD
Salmeterol—Nausea—Lovastatin—atherosclerosis	0.000283	0.00138	CcSEcCtD
Salmeterol—Rash—Simvastatin—atherosclerosis	0.000281	0.00137	CcSEcCtD
Salmeterol—Dermatitis—Simvastatin—atherosclerosis	0.000281	0.00137	CcSEcCtD
Salmeterol—Diarrhoea—Niacin—atherosclerosis	0.00028	0.00137	CcSEcCtD
Salmeterol—Headache—Simvastatin—atherosclerosis	0.00028	0.00136	CcSEcCtD
Salmeterol—Nausea—Ezetimibe—atherosclerosis	0.000278	0.00136	CcSEcCtD
Salmeterol—Diarrhoea—Pravastatin—atherosclerosis	0.000276	0.00135	CcSEcCtD
Salmeterol—Dizziness—Niacin—atherosclerosis	0.000271	0.00132	CcSEcCtD
Salmeterol—Dizziness—Pravastatin—atherosclerosis	0.000267	0.0013	CcSEcCtD
Salmeterol—Nausea—Simvastatin—atherosclerosis	0.000265	0.00129	CcSEcCtD
Salmeterol—Vomiting—Niacin—atherosclerosis	0.000261	0.00127	CcSEcCtD
Salmeterol—Rash—Niacin—atherosclerosis	0.000258	0.00126	CcSEcCtD
Salmeterol—Dermatitis—Niacin—atherosclerosis	0.000258	0.00126	CcSEcCtD
Salmeterol—Headache—Niacin—atherosclerosis	0.000257	0.00125	CcSEcCtD
Salmeterol—Vomiting—Pravastatin—atherosclerosis	0.000257	0.00125	CcSEcCtD
Salmeterol—Rash—Pravastatin—atherosclerosis	0.000254	0.00124	CcSEcCtD
Salmeterol—Dermatitis—Pravastatin—atherosclerosis	0.000254	0.00124	CcSEcCtD
Salmeterol—Headache—Pravastatin—atherosclerosis	0.000253	0.00123	CcSEcCtD
Salmeterol—Nausea—Niacin—atherosclerosis	0.000243	0.00119	CcSEcCtD
Salmeterol—Nausea—Pravastatin—atherosclerosis	0.00024	0.00117	CcSEcCtD
Salmeterol—ADRB2—Signaling Pathways—APOA2—atherosclerosis	1.97e-05	0.000805	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LCAT—atherosclerosis	1.96e-05	0.000802	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—FABP4—atherosclerosis	1.96e-05	0.000802	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALOX5—atherosclerosis	1.95e-05	0.000797	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOA4—atherosclerosis	1.93e-05	0.000787	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	1.9e-05	0.000777	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP7A1—atherosclerosis	1.89e-05	0.000773	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—KNG1—atherosclerosis	1.89e-05	0.00077	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—UTS2—atherosclerosis	1.88e-05	0.000768	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AGTR1—atherosclerosis	1.87e-05	0.000766	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCG1—atherosclerosis	1.81e-05	0.000739	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CX3CR1—atherosclerosis	1.8e-05	0.000736	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASR—atherosclerosis	1.8e-05	0.000736	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CX3CL1—atherosclerosis	1.77e-05	0.000722	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NAMPT—atherosclerosis	1.75e-05	0.000715	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—EDN1—atherosclerosis	1.75e-05	0.000715	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP27A1—atherosclerosis	1.75e-05	0.000715	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—LIPC—atherosclerosis	1.74e-05	0.000711	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CCL5—atherosclerosis	1.74e-05	0.000709	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOC3—atherosclerosis	1.73e-05	0.000706	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—LDLR—atherosclerosis	1.72e-05	0.000702	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—FABP4—atherosclerosis	1.7e-05	0.000695	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LCAT—atherosclerosis	1.7e-05	0.000695	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CETP—atherosclerosis	1.68e-05	0.000686	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CNR2—atherosclerosis	1.67e-05	0.000684	CbGpPWpGaD
Salmeterol—ADRB2—GPCR ligand binding—CXCL8—atherosclerosis	1.67e-05	0.000684	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MMP3—atherosclerosis	1.67e-05	0.000683	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOA4—atherosclerosis	1.67e-05	0.000682	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALOX5AP—atherosclerosis	1.66e-05	0.000678	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PLA2G2A—atherosclerosis	1.66e-05	0.000678	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOA2—atherosclerosis	1.66e-05	0.000678	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALOX15—atherosclerosis	1.66e-05	0.000678	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PRKCG—atherosclerosis	1.65e-05	0.000674	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP7A1—atherosclerosis	1.64e-05	0.00067	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCG5—atherosclerosis	1.64e-05	0.000669	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—SCARB1—atherosclerosis	1.61e-05	0.000656	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EDN1—atherosclerosis	1.59e-05	0.000649	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LPA—atherosclerosis	1.58e-05	0.000647	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CCL5—atherosclerosis	1.58e-05	0.000644	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	1.56e-05	0.000638	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—BGN—atherosclerosis	1.53e-05	0.000626	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HMGCR—atherosclerosis	1.52e-05	0.00062	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOA5—atherosclerosis	1.52e-05	0.00062	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP27A1—atherosclerosis	1.52e-05	0.000619	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LDLRAP1—atherosclerosis	1.51e-05	0.000615	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PRKCG—atherosclerosis	1.5e-05	0.000612	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VWF—atherosclerosis	1.49e-05	0.00061	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	1.49e-05	0.00061	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOC3—atherosclerosis	1.48e-05	0.000606	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LDLR—atherosclerosis	1.47e-05	0.000602	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PLA2G1B—atherosclerosis	1.46e-05	0.000597	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	1.46e-05	0.000595	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AGT—atherosclerosis	1.45e-05	0.000593	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCL3—atherosclerosis	1.44e-05	0.000588	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALOX15—atherosclerosis	1.44e-05	0.000587	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOA2—atherosclerosis	1.44e-05	0.000587	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PLA2G2A—atherosclerosis	1.44e-05	0.000587	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALOX5AP—atherosclerosis	1.44e-05	0.000587	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCG5—atherosclerosis	1.42e-05	0.00058	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	1.42e-05	0.000579	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PLTP—atherosclerosis	1.42e-05	0.000579	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALOX5—atherosclerosis	1.41e-05	0.000576	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NCF1—atherosclerosis	1.38e-05	0.000563	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LPA—atherosclerosis	1.37e-05	0.00056	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ABCA1—atherosclerosis	1.35e-05	0.000553	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—F2—atherosclerosis	1.34e-05	0.000548	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—BGN—atherosclerosis	1.33e-05	0.000542	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AGT—atherosclerosis	1.32e-05	0.000539	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	1.32e-05	0.000538	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOA5—atherosclerosis	1.31e-05	0.000537	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EDNRA—atherosclerosis	1.3e-05	0.000532	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCR2—atherosclerosis	1.3e-05	0.000532	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CYBA—atherosclerosis	1.3e-05	0.00053	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CG—atherosclerosis	1.28e-05	0.000525	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	1.28e-05	0.000521	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PARP1—atherosclerosis	1.27e-05	0.000519	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PLAT—atherosclerosis	1.27e-05	0.000519	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GHRL—atherosclerosis	1.27e-05	0.000519	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NAMPT—atherosclerosis	1.26e-05	0.000517	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PLA2G1B—atherosclerosis	1.26e-05	0.000517	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LIPC—atherosclerosis	1.26e-05	0.000514	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	1.25e-05	0.000511	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOC3—atherosclerosis	1.25e-05	0.00051	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LDLR—atherosclerosis	1.24e-05	0.000507	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	1.24e-05	0.000506	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	1.24e-05	0.000505	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LTA4H—atherosclerosis	1.23e-05	0.000502	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCG8—atherosclerosis	1.23e-05	0.000502	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALOX5—atherosclerosis	1.22e-05	0.000499	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—F2—atherosclerosis	1.22e-05	0.000498	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CETP—atherosclerosis	1.21e-05	0.000496	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CG—atherosclerosis	1.17e-05	0.000477	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SCARB1—atherosclerosis	1.16e-05	0.000475	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—HMOX1—atherosclerosis	1.16e-05	0.000474	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	1.13e-05	0.000461	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KNG1—atherosclerosis	1.11e-05	0.000455	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOB—atherosclerosis	1.11e-05	0.000454	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AGTR1—atherosclerosis	1.11e-05	0.000452	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMGCR—atherosclerosis	1.1e-05	0.000448	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NAMPT—atherosclerosis	1.1e-05	0.000448	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	1.09e-05	0.000445	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LIPC—atherosclerosis	1.09e-05	0.000445	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CCL2—atherosclerosis	1.09e-05	0.000444	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOC3—atherosclerosis	1.08e-05	0.000442	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTM1—atherosclerosis	1.08e-05	0.000442	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PLG—atherosclerosis	1.08e-05	0.000441	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LDLR—atherosclerosis	1.08e-05	0.000439	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—LPL—atherosclerosis	1.06e-05	0.000434	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CETP—atherosclerosis	1.05e-05	0.000429	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GPX1—atherosclerosis	1.04e-05	0.000423	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SOCS3—atherosclerosis	1.02e-05	0.000418	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CD36—atherosclerosis	1.01e-05	0.000412	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SCARB1—atherosclerosis	1.01e-05	0.000411	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP3—atherosclerosis	9.87e-06	0.000403	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF2—atherosclerosis	9.83e-06	0.000401	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	9.79e-06	0.0004	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ABCA1—atherosclerosis	9.78e-06	0.000399	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCG1—atherosclerosis	9.71e-06	0.000397	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—MTHFR—atherosclerosis	9.55e-06	0.00039	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOB—atherosclerosis	9.54e-06	0.00039	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMGCR—atherosclerosis	9.5e-06	0.000388	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCL8—atherosclerosis	9.46e-06	0.000386	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EDN1—atherosclerosis	9.39e-06	0.000384	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARA—atherosclerosis	9.37e-06	0.000383	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCL5—atherosclerosis	9.31e-06	0.000381	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—FABP4—atherosclerosis	9.13e-06	0.000373	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LCAT—atherosclerosis	9.13e-06	0.000373	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LPL—atherosclerosis	9.11e-06	0.000372	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AGT—atherosclerosis	9.08e-06	0.000371	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOA4—atherosclerosis	8.96e-06	0.000366	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOE—atherosclerosis	8.89e-06	0.000363	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PRKCG—atherosclerosis	8.86e-06	0.000362	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CAV1—atherosclerosis	8.81e-06	0.00036	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP7A1—atherosclerosis	8.8e-06	0.00036	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—APOA1—atherosclerosis	8.79e-06	0.000359	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SPP1—atherosclerosis	8.63e-06	0.000352	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL8—atherosclerosis	8.59e-06	0.000351	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	8.57e-06	0.00035	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ABCA1—atherosclerosis	8.47e-06	0.000346	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—HMOX1—atherosclerosis	8.39e-06	0.000343	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP27A1—atherosclerosis	8.13e-06	0.000332	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOB—atherosclerosis	8.03e-06	0.000328	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CG—atherosclerosis	8.03e-06	0.000328	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFB—atherosclerosis	7.98e-06	0.000326	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTM1—atherosclerosis	7.81e-06	0.000319	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AGT—atherosclerosis	7.79e-06	0.000318	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARG—atherosclerosis	7.75e-06	0.000317	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALOX15—atherosclerosis	7.71e-06	0.000315	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOA2—atherosclerosis	7.71e-06	0.000315	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	7.71e-06	0.000315	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	7.71e-06	0.000315	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LPL—atherosclerosis	7.67e-06	0.000313	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LEP—atherosclerosis	7.63e-06	0.000312	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOE—atherosclerosis	7.63e-06	0.000312	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCG5—atherosclerosis	7.62e-06	0.000311	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—INS—atherosclerosis	7.6e-06	0.00031	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CAV1—atherosclerosis	7.56e-06	0.000309	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APOA1—atherosclerosis	7.55e-06	0.000308	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GPX1—atherosclerosis	7.48e-06	0.000306	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LPA—atherosclerosis	7.36e-06	0.000301	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ESR1—atherosclerosis	7.29e-06	0.000298	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CD36—atherosclerosis	7.29e-06	0.000298	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HMOX1—atherosclerosis	7.26e-06	0.000297	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—F2—atherosclerosis	7.2e-06	0.000294	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—BGN—atherosclerosis	7.12e-06	0.000291	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOA5—atherosclerosis	7.05e-06	0.000288	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ALB—atherosclerosis	6.97e-06	0.000285	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOB—atherosclerosis	6.96e-06	0.000284	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MTHFR—atherosclerosis	6.91e-06	0.000282	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CG—atherosclerosis	6.89e-06	0.000282	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	6.79e-06	0.000277	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARA—atherosclerosis	6.78e-06	0.000277	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTM1—atherosclerosis	6.77e-06	0.000277	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NOS3—atherosclerosis	6.66e-06	0.000272	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LPL—atherosclerosis	6.64e-06	0.000271	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MAPK3—atherosclerosis	6.6e-06	0.00027	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AGT—atherosclerosis	6.56e-06	0.000268	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALOX5—atherosclerosis	6.56e-06	0.000268	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—INS—atherosclerosis	6.52e-06	0.000266	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GPX1—atherosclerosis	6.48e-06	0.000265	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOE—atherosclerosis	6.43e-06	0.000263	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCL2—atherosclerosis	6.42e-06	0.000262	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CAV1—atherosclerosis	6.37e-06	0.00026	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—APOA1—atherosclerosis	6.36e-06	0.00026	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CD36—atherosclerosis	6.31e-06	0.000258	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1—atherosclerosis	6.31e-06	0.000258	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—atherosclerosis	6.09e-06	0.000249	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SERPINE1—atherosclerosis	5.99e-06	0.000245	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTHFR—atherosclerosis	5.98e-06	0.000244	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.88e-06	0.00024	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARA—atherosclerosis	5.87e-06	0.00024	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LIPC—atherosclerosis	5.84e-06	0.000239	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOC3—atherosclerosis	5.81e-06	0.000237	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CG—atherosclerosis	5.8e-06	0.000237	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LDLR—atherosclerosis	5.77e-06	0.000236	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOS3—atherosclerosis	5.72e-06	0.000234	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AGT—atherosclerosis	5.68e-06	0.000232	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CETP—atherosclerosis	5.64e-06	0.00023	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARG—atherosclerosis	5.6e-06	0.000229	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOE—atherosclerosis	5.57e-06	0.000228	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CAV1—atherosclerosis	5.52e-06	0.000225	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—APOA1—atherosclerosis	5.51e-06	0.000225	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—INS—atherosclerosis	5.49e-06	0.000224	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SCARB1—atherosclerosis	5.4e-06	0.000221	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.1e-06	0.000208	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	5.07e-06	0.000207	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ALB—atherosclerosis	5.04e-06	0.000206	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CG—atherosclerosis	5.03e-06	0.000205	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	4.9e-06	0.0002	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARG—atherosclerosis	4.85e-06	0.000198	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6—atherosclerosis	4.82e-06	0.000197	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NOS3—atherosclerosis	4.82e-06	0.000197	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—INS—atherosclerosis	4.76e-06	0.000194	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—atherosclerosis	4.59e-06	0.000187	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.54e-06	0.000186	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	4.54e-06	0.000185	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	4.46e-06	0.000182	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	4.45e-06	0.000182	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—atherosclerosis	4.41e-06	0.00018	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ALB—atherosclerosis	4.36e-06	0.000178	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NOS3—atherosclerosis	4.17e-06	0.00017	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	4.12e-06	0.000168	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT3—atherosclerosis	4.08e-06	0.000167	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.9e-06	0.000159	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	3.9e-06	0.000159	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—atherosclerosis	3.82e-06	0.000156	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	3.78e-06	0.000155	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOB—atherosclerosis	3.73e-06	0.000153	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.63e-06	0.000148	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LPL—atherosclerosis	3.57e-06	0.000146	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GPX1—atherosclerosis	3.48e-06	0.000142	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CD36—atherosclerosis	3.39e-06	0.000138	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.21e-06	0.000131	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARA—atherosclerosis	3.15e-06	0.000129	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKT1—atherosclerosis	3.06e-06	0.000125	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AGT—atherosclerosis	3.05e-06	0.000125	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOE—atherosclerosis	2.99e-06	0.000122	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CAV1—atherosclerosis	2.96e-06	0.000121	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—APOA1—atherosclerosis	2.95e-06	0.000121	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6—atherosclerosis	2.85e-06	0.000116	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.7e-06	0.00011	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT1—atherosclerosis	2.63e-06	0.000107	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARG—atherosclerosis	2.6e-06	0.000106	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—INS—atherosclerosis	2.55e-06	0.000104	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ALB—atherosclerosis	2.34e-06	9.57e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NOS3—atherosclerosis	2.24e-06	9.15e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKT1—atherosclerosis	2.21e-06	9.05e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.05e-06	8.37e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKT1—atherosclerosis	1.92e-06	7.84e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKT1—atherosclerosis	1.03e-06	4.21e-05	CbGpPWpGaD
